Clinical Trial

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated August 9, 2024 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of SHR-A1921 versus investigator's choice of chemotherapy in patients with platinum-resistant recurrent epithelial ovarian cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-27.
Status change: Not Yet Recruiting → Recruiting 2024-08-08
Trial Details
NCT Number NCT06394492
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Ovarian Cancer
Enrollment 440 participants
Start Date 2024-05-10
Primary Completion 2026-05-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-09